Apellis Pharmaceuticals Inc (APLS) — Cash Flow Reinvestment Rate

Latest as of September 2025: 0.00x

Apellis Pharmaceuticals Inc (APLS) has a Cash Flow Reinvestment Rate of 0.00x as of September 2025, reinvesting $296.00K (capex $148.00K plus investments $-148.00K) from operating cash flow of $108.47 Million. Explore APLS capex reinvestment rate to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

0.00x
(Capex + Investments) / Operating CF

Total Reinvested

$296.00K
Capex + Investments

Operating Cash Flow

$108.47 Million
USD

Capital Expenditures

$148.00K
USD

Apellis Pharmaceuticals Inc Cash Flow Reinvestment Rate (2025–2025)

Historical reinvestment intensity for Apellis Pharmaceuticals Inc across 1 annual periods. Also explore Apellis Pharmaceuticals Inc (APLS) total assets for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for Apellis Pharmaceuticals Inc (2025–2025)

Year-by-year capital reinvestment analysis for Apellis Pharmaceuticals Inc. For live market cap and broader valuation context, see Apellis Pharmaceuticals Inc (APLS) market capitalisation.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2025 0.01x $313.00K $45.33 Million $313.00K
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow